Andrew S. Davis - 03 Apr 2023 Form 4 Insider Report for Silk Road Medical Inc

Role
Chief Commercial Officer
Signature
/s/ Mhairi Jones, by power of attorney
Issuer symbol
N/A
Transactions as of
03 Apr 2023
Net transactions value
-$233,831
Form type
4
Filing time
05 Apr 2023, 17:19:00 UTC
Previous filing
06 Mar 2023
Next filing
03 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SILK Common Stock Options Exercise $1,906 +312 +0.27% $6.11 115,995 03 Apr 2023 Direct F1
transaction SILK Common Stock Options Exercise $6,977 +1,475 +1.3% $4.73 117,470 03 Apr 2023 Direct F1
transaction SILK Common Stock Options Exercise $23,489 +4,966 +4.2% $4.73 122,436 03 Apr 2023 Direct F1
transaction SILK Common Stock Sale $12,299 -312 -0.25% $39.42 122,124 03 Apr 2023 Direct F1, F2
transaction SILK Common Stock Sale $58,144 -1,475 -1.2% $39.42 120,649 03 Apr 2023 Direct F1, F2
transaction SILK Common Stock Sale $195,760 -4,966 -4.1% $39.42 115,683 03 Apr 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SILK Option (right to buy) Options Exercise $0 -1,475 -3% $0.000000 47,451 03 Apr 2023 Common Stock 1,475 $4.73 Direct F1, F3
transaction SILK Option (right to buy) Options Exercise $0 -4,966 -19% $0.000000 21,304 03 Apr 2023 Common Stock 4,966 $4.73 Direct F1, F3
transaction SILK Option (right to buy) Options Exercise $0 -312 -12% $0.000000 2,335 03 Apr 2023 Common Stock 312 $6.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on May 20, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
F2 This transaction was executed in multiple trades at price ranging from $38.67 to $40.29. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 All of the shares subject to the option and fully vested and exercisable as of the date hereof.